Rifabutin receives treatment IND status for AIDS-related use.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000995:Antitubercular Agents / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D015269:Mycobacterium avium Complex; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy; D017828:Rifabutin; D012294:Rifamycins / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000995:Antitubercular Agents; D015507:Drugs, Investigational; D012294:Rifamycins; D017828:Rifabutin